Equities Analysts Offer Predictions for STOK FY2025 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Chardan Capital issued their FY2025 earnings per share (EPS) estimates for Stoke Therapeutics in a report released on Wednesday, November 19th. Chardan Capital analyst K. Nakae anticipates that the company will post earnings of $0.40 per share for the year. Chardan Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. Chardan Capital also issued estimates for Stoke Therapeutics’ FY2026 earnings at ($2.30) EPS.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.11). Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%.The business had revenue of $10.63 million for the quarter, compared to the consensus estimate of $6.06 million.

A number of other equities analysts also recently commented on the stock. Wedbush boosted their price objective on shares of Stoke Therapeutics from $22.00 to $32.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 5th. JPMorgan Chase & Co. lifted their price target on Stoke Therapeutics from $15.00 to $25.00 and gave the company a “neutral” rating in a report on Monday, November 3rd. Canaccord Genuity Group upped their price objective on Stoke Therapeutics from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Stoke Therapeutics in a research report on Wednesday, November 19th. Finally, Needham & Company LLC raised their price target on shares of Stoke Therapeutics from $22.00 to $35.00 and gave the company a “buy” rating in a report on Friday, October 10th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $31.00.

Stoke Therapeutics Stock Performance

Shares of STOK opened at $29.82 on Monday. The company has a 50 day moving average price of $27.80 and a 200-day moving average price of $18.78. Stoke Therapeutics has a fifty-two week low of $5.35 and a fifty-two week high of $38.69. The stock has a market capitalization of $1.70 billion, a PE ratio of 44.51 and a beta of 1.32.

Institutional Investors Weigh In On Stoke Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Corient Private Wealth LLC acquired a new position in shares of Stoke Therapeutics in the 2nd quarter valued at $7,489,000. Wellington Management Group LLP lifted its position in Stoke Therapeutics by 438.2% during the 3rd quarter. Wellington Management Group LLP now owns 737,753 shares of the company’s stock worth $17,337,000 after acquiring an additional 600,687 shares during the period. Polar Capital Holdings Plc grew its stake in Stoke Therapeutics by 49.8% during the 3rd quarter. Polar Capital Holdings Plc now owns 1,323,470 shares of the company’s stock valued at $31,102,000 after purchasing an additional 439,824 shares during the last quarter. Checkpoint Capital L.P. increased its holdings in shares of Stoke Therapeutics by 139.3% in the first quarter. Checkpoint Capital L.P. now owns 730,717 shares of the company’s stock valued at $4,859,000 after purchasing an additional 425,330 shares during the period. Finally, Erste Asset Management GmbH acquired a new position in shares of Stoke Therapeutics in the first quarter valued at about $2,670,000.

Insiders Place Their Bets

In related news, insider Barry Ticho sold 5,931 shares of the stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $25.72, for a total value of $152,545.32. Following the completion of the transaction, the insider directly owned 7,195 shares of the company’s stock, valued at $185,055.40. This trade represents a 45.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Edward M. Md Kaye sold 25,000 shares of Stoke Therapeutics stock in a transaction that occurred on Wednesday, October 8th. The stock was sold at an average price of $30.00, for a total transaction of $750,000.00. Following the completion of the sale, the director owned 49,124 shares of the company’s stock, valued at $1,473,720. This trade represents a 33.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 213,367 shares of company stock valued at $5,110,464. 9.50% of the stock is owned by corporate insiders.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.